Eli Lilly is trading at ARS 38,640.00, up 4.15%, amid positive Phase 3 sub-study results indicating retatrutide reduced breathing interruptions in people with obesity and obstructive sleep apnea.
- The company broke ground on a $5 billion Virginia manufacturing facility on October 22, expanding U.S. production capacity.
- These company-specific developments provide a plausible positive catalyst as broader markets fell; available reporting does not establish how much each announcement contributed to the live move.